Kornimate/medical-research-clean huggingface dataset:
n-acetylcysteine in heart failure with coexistent chronic renal failure

Conditions: Heart Failure, Congestive; Kidney Failure, Chronic

Summary: treatment with n-acetylcysteine in patients with heart failure and chronic renal failure leads to improvements in vascular function and in renal function.

ten patients will be invited to participate in the trial. after obtaining informed consent, the ten patients will be randomly assigned to one month of treatment with oral n-acetylcysteine 500mg or placebo twice daily for thirty days in addition to their regular therapy. at enrolment the patients will be educated and counselled about the trial and the intervention medication. patients will also have a blood test (serum creatinine) that will allow the calculation of their renal function by use of the cockroft gault equation. blood samples will also be frozen and stored. patients will also undergo an ultrasound test of the function of their arm blood vessels. both the blood test and the ultrasound test will be repeated at the completion of the thirty day trial period. again the blood test sample will be frozen and stored. subjects will then cross over to the other treatment arm for a further one month period, with the same testing at the end.

Eligibility criteria:
inclusion criteria: * age 18 to 75 years inclusive; * patients with chronic heart failure nyha ii, iii and iv and lvef\<40%. stable medications for 1 month. not admitted to hospital in the past month. * chronic renal failure with gfr (as estimated by the cockroft gault equation) of \>30 ml/min and \<50 ml/min not on any form of dialysis. exclusion criteria: * age \ 75 years; * myocardial infarction in the preceding six months; * acute decompensation of renal function or heart failure in the last 30 days; * allergy to n-acetylcysteine or glyceryl trinitrate; * contraindications to the use of glyceryl trinitrate as per the product information lodged with the pbs (australia); * on treatment with allopurinol, vitamin c or vitamin e or other antioxidant therapy at time of randomisation (statins are acceptable); * acute decompensation of another organ system in the last 30 days; * current pregnancy.

Keywords: acetylcysteine n-acetylcysteine heart failure renal failure
effect of ursodeoxycholic acid on preventing covid-19 infection in patients with organ transplantation

Conditions: Organ Transplantation; COVID-19

Summary: ursodeoxycholic acid is a clinically approved drug which widely used in patients with chronic liver diseases, especially liver transplantation. in china, the covid-19 infection is in an epidemic state, and the population is generally susceptible to covid-19. more attention needs to be paid to the prevalence and severity of people taking immunosuppressants after organ transplantation. recent cohort studies and experiments based on tissue cells, animals and human beings suggest that ursodeoxycholic acid has the potential ability to prevent the entry of covid-19 into cells, revealing that ursodeoxycholic acid may be used to prevent the covid-19 infection. based on the medical records of patients( already registered on the management website http://www.cltr.org or www.csrkt.org.cn) who received organ transplantation in the first affiliated hospital of xi'an jiaotong university and the first affiliated hospital of zhengzhou university, this project intends to collect information and data from patients received organ transplantation, aim to understand the covid-19 infection and severe condition of organ transplantation patients, also explore whether ursodeoxycholic acid has preventive and therapeutic effects on covid-19 infection and severity rate in patients. this research provides a theoretical basis for further standardizing the prevention and treatment of covid-19 in patients received organ transplantation.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years; 2. patients received liver or renal transplantation from 2015 to 2022 exclusion criteria: 1.age \< 18 years; 2. multi-organ transplantation; 3. patients with incomplete information or loss of follow-up; 4.covid-19 infection before organ transplantation; 5. patients hospitalized with rejection or other infection within two weeks before covid-19 diagnosis.

Keywords: ursodeoxycholic acid covid-19 organ transplantation immunosuppression
psma-pet guided radiotherapy

Conditions: Prostate Cancer

Summary: psma pet/ct has demonstrated higher sensitivity in detecting metastases than current imaging standard of care (ct and bone scan). \[18f\]dcfpyl is a promising high-sensitivity second generation psma-targeted urea-based pet probe. the hypothesis is that definitive radiotherapy (rt) informed by psma-pet findings will lead to improved cancer control outcomes compared to rt guided by conventional staging only. this study utilizes cmrct design in companion to pera (partnership initiative for the evaluation of technological innovation in radiotherapy).


Eligibility criteria:
inclusion criteria: 1. enrolled in pera (chum cer 17.0.32) and consented to contact for investigational trials. 2. histological diagnosis of prostate cancer planned for curative-intent radiotherapy. 3. ecog 0-1 4. charlson cormobidity index ≤ 4 5. high-risk of distant metastases as defined by any of: 1. oligometastases (≤5) (regional or distant) identified on conventional staging, with ≤ 3 metastasis in any non-bone organ. for a spine metastasis, direct involvement of adjacent spinal segments would still be considered as "one" tumour. for nodal metastases, more than one involved lymph node in the same ipsilateral nodal region/chain would still count as "one" tumour. defined nodal regions for this protocol include inguinal, external iliac, internal iliac, common iliac, retroperitoneal, hilar/mediastinal, anterior cervical, posterior cervical, and axillary. metastases in all other organs that are within 1cm of each other will be considered as "one" tumour. 2. subjects with newly diagnosed high-risk (nccn) localized prostate cancer and capra score 6-10. 3. subjects with a prior history of treated prostate cancer (rp or rt), and biochemical failure (phoenix-rt or\>0.2ng/ml-rp) 6. standard staging (bone scan, ct pelvis) within 12 weeks of consent. exclusion criteria: 1. prior androgen deprivation therapy terminated \< 12 months prior to enrollment. 2. prior or planned pet scan.
re-mineralization effects of sugar free chewing gum sweetened with different sugar-substitutes

Conditions: Re-mineralization

Summary: the purpose of this study is to evaluate the clinical effect of chewing gum containing maltitol, on re-mineralization of early caries following daily chewing for 6 months by school children, compared to a xylitol gum, gum base and a no gum group.


Eligibility criteria:
inclusion criteria: * consent informed consent form signed by parent or legal guardian permitting participation of their children. * be cooperative and able to be examined in the whole study duration. * aged from 8 to 13 years. * general health: good general health (in the opinion of the investigator) without clinically significant and relevant abnormalities of medical history such as diabetic, etc. * oral health: display 6 permanent front teeth and two maxillary buccal surfaces with visual evidence of active initial enamel carious lesions (de-mineralized but not cavitated); no any form of intraoral prostheses or appliances, clinical signs of severe gingivitis or periodontitis, temporomandibular joint disorders, and malocclusions or chronic onychophagia * oral hygiene: have good oral health habits, brushing teeth at least once per day * no medical or pharmacotherapy history that might affect the outcomes of the study, e.g. use of mouthwash, gels, or chewing gum containing antimicrobial agents during the previous 3 months exclusion criteria: * disease: presence of chronic debilitating disease, or any condition or other chronic disease which the investigators think not suitable for the study. * allergy/intolerance: be allergic to both maltitol and xylitol, oral care products, personal care consumer products, or their ingredients. * current product use: usual chewing-gum (of any kind) consumer or sugars-free candies consumer * clinical study/experiment: participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.

Keywords: maltitol xylitol quantitative light-induced fluorescence saliva ph re-mineralization dental caries
effect of food, gender, and age on the pharmacokinetic profile of suvn-911 in healthy subjects

Conditions: Major Depressive Disorder

Summary: the purpose of the study is to investigate the effect of food, gender, and age on the pharmacokinetic profile of suvn-911 in healthy subjects

this is a phase i, single-center, open-label, single dose study to evaluate the effect of food, gender, and age on the safety and pharmacokinetic profiles of single doses of suvn-911, administered orally in healthy subjects. the primary objective is to evaluate the effect of food, gender, and age on the pharmacokinetics of a single dose of suvn-911 administered orally to healthy subjects. the secondary objective is to evaluate the safety and tolerability of a single dose of suvn-911 administered orally to healthy adult male, female, and elderly subjects

Eligibility criteria:
inclusion criteria: healthy male subjects, 18 to 45 years of age (inclusive) for cohort 1, healthy female subjects, 18 to 45 years of age (inclusive) for cohort 2, and healthy male subjects ≥ 65 years of age (inclusive) for cohort 3, at the time of signing the informed consent. subjects in cohorts 1 and 2 must have a body weight of at least 50 kg and body mass index (bmi) within the range of 18 to 30 kg/m2 (inclusive). elderly subjects in cohort 3 must have a body weight of at least 50 kg and bmi within the range of 18 to 32 kg/m2 (inclusive) exclusion criteria: history of any important clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study. history or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs. any clinically important illness, medical/surgical procedure, or trauma within 28 days of the first administration of the study treatment (day 1). any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results as judged by the investigator. any positive result at screening for serum hepatitis b surface antigen (hbsag), hepatitis c virus (hcv) antibody, and human immunodeficiency virus (hiv) antibody.

Keywords: suvn-911 depression alpha4 beta2 receptor
prophylactic evozac® calming skin spray for egfr-tkis associated rash eruption in nsclc

Conditions: Non-small Cell Lung Cancer

Summary: the epidermal growth factor receptor (egfr) has become an important target for cancer therapy, and the small molecular tyrosine kinase inhibitors (egfr-tkis) have played an important role in the treatment of non-small cell lung cancer (nsclc). what accompanies with the encouraging efficacy in nsclc is the common side effects, of which the most common one is the specific papular and pustular acne-like rash which affects mainly the face, scalp, and upper torso. but till now, no medicament has been proved effective enough to treat or prevent the egfr-tkis associated rash. the evozac® calming skin spray has shown acceptable activity at the rash prevention in our preliminary study, so the investigators conduct the randomized, double-blind, controlled trial to evaluate the efficacy and safety of evozac® calming skin spray in prevention of egfr-tkis associated rash in nsclc.

not suitable: no more information is needed to be described.

Eligibility criteria:
inclusion criteria: * histologically proven nsclc diagnosis * life expectancy over four weeks * absolute neutrophil count ≥ 2.0x109/l, pt ≥ 100x109/l, hemoglobin ≥ 90g/l * with normal hepatic function(ast, alt \< 2.5 x upper limit of normal , and total bilirubin ≤ upper limit of normal) * suitable for egfr-tkis treatment and expectant duration over four weeks * no specific therapies received within 4 weeks prior to enrollment which may induce similar skin reaction,such as cetuximab, sorafenib, avastin. * with a pre-existing peripheral neuropathy (national cancer institute common toxicity criteria for adverse events \[nci-ctc\] grade ≥ 3) * no other concomitant therapy referred to the face skin during the study * signed and dated informed consent exclusion criteria: * performance status ≥ 3(ecog) * pregnant or breast-feeding patients * the lesion counts can't be evaluated due to concomitant diseases or other conditions * not suitable for egfr-tkis treatment
hiv pre-exposure prophylaxis implementation hong kong study

Conditions: HIV Infections

Summary: while pre-exposure prophylaxis (prep) is widely recommended and a number of pilot studies are on-going worldwide, progress of its implementation in the real world setting has been slow, especially in asia. this study aims to develop a service model for prep delivery and test its operability in the real world setting. in this implementation study, 400 individuals with high sexual risk of hiv infection who fulfil eligibility criteria would be recruited. eligible participants would receive one year of daily tenofovir disoproxil fumarate 300mg / emtricitabine 200mg (tdf/ftc) for free. a client-initiated approach would be adopted, requiring participants to self-arrange for regular hiv/sexually transmitted infections (sti) testing. an online system would be developed to facilitate participants to plan for testing and consultation for accessing prep. questionnaire at baseline and subsequent monthly follow-up would be administered to assess behaviour, monitor adverse effects and drug adherence, the latter coupled with the completion of an online diary. testing of hiv and creatinine would be performed using point-of-care test or by phlebotomy during clinical visits. blood samples would be collected for archiving. around 40 participants would be invited to join an in-depth interview in the later part of the study to evaluate the service model. the main outcome measures are: prep service adherence, prep drug adherence, prevalence of drug intolerance, prevalence of unprotected sex in the study period, incidence of hiv and sti


Eligibility criteria:
inclusion criteria: * can communicate in written and spoken english or chinese * is normally resident in hong kong * has tested hiv antibody negative in the past 3 months * has more than 1 episode of unprotected sex (especially anal sex) in the preceding 6 months * has any one of the following experiences in the past 6 months: chemsex engagement, group sex, multiple sex partners, sti diagnosis, having sex partner(s) with hiv+ve status * is inclined to engage in high risk sexual activities exclusion criteria: * chronic hbv infection (hbsag +ve) * impaired renal function, defined as estimated glomerular filtration rate (egfr) \< 60ml/min/1.73m2 * having any form of mental illnesses * inability or refusal to give consent * prisoners or any institutionalised persons * pregnant or planning to get pregnant (for female) * injection drug user

Keywords: hiv pre-exposure prophylaxis adherence antiretroviral
study of folic acid, calcium and vitamin d in preventing colorectal polyps and colorectal cancer

Conditions: Colorectal Neoplasms

Summary: folic acid (fa) and its derivatives (folate) which play a role in nucleotide synthesis and methylation reactions as well as calcium and vitamin d are assumed to be effective in the prevention of colorectal polyps and colorectal cancer (crc). the aim of this study is to investigate the roles of fa as well as calcium and vitamin d in the prevention of crc.

colorectal cancer (crc) affects approximately one million people each year with a five-year survival rate of 62% . considerable interest has recently been focused on the relationship between the chemoprevention of colorectal polyps/cra and crc. therefore, the use of nutritional compounds which are usually less afflicted with the risk of severe side effects for colorectal adenoma (cra) prevention and health maintenance is an emerging field.

Eligibility criteria:
inclusion criteria: * individuals aged 50-80 years * patients had undergone complete colonoscopy with no adenoma found * those who voluntarily sign the consent form after being fully informed and understanding the purpose and procedures of the study, characters of the disease, effect of medications, methods of related examinations, and potential risk/benefits of the study exclusion criteria: * patients who are hypersensitive or intolerant to the drugs * patients who are intolerant to another colonoscopy examination * pregnant women, woman during breast-feeding period, or women with expect pregnancy * patients with diabetes mellitus, severe heart or renal disease，or cancer history * patients with malignant neoplasm, or suspicious colorectal cancer * patients who are not able to cooperate * individuals who are involved in designing, planning or performing this experiment * patients with medical conditions who are not appropriate to participate the study * patients who are take aspirin or cyclooxygenase 2 inhibitor （cox2）.
use of telmisartan and captopril in inflammation of hemodialysis patients

Conditions: Inflammation; End-stage Renal Disease

Summary: the aim of this study was to compare the dual use of telmisartan and captopril vs the individual use of such drugs and placebo on the systemic inflammation of patients on hemodialysis (hd).

once included, patients will be randomly allocated (by a computer-generated randomization list) to one of the following groups: group 1 will receive captopril, group 2 telmisartan, group 3 captopril plus telmisartan, and group 4 placebo. drugs will be provided as tablets during a period of 3 months. all patients will have 3 hd sessions per week, with the same kind of single-use dialysis membrane and dialysate monthly visits will be scheduled for clinical and biochemical evaluations. a blood sample will be taken at baseline and every month for measurement of complete blood count, urea, creatinine, glucose, albumin, lipids, and electrolytes (measured by usual methods). in serum samples at 0, 1 and 3 months, tumor necrosis factor alpha (tnf-α) and interleukin 6 (il-6) concentrations will be measured by elisa using high sensitivity kits. additionally, in the same serum samples, c-reactive protein (crp) concentrations will be measured by nephelometry using high sensitivity kits. all laboratory measurements, including inflammation markers, will be performed in the central laboratory (hospital de especialidades, centro médico nacional de occidente), by the same personnel blinded to patient's details. treatment compliance will be recorded by counting tablets left in the container at the end of each monthly visit.

Eligibility criteria:
inclusion criteria: * age ≥18 years * ≥2 months on hemodialysis * arteriovenous fistula as vascular access * endorsement of informed consent exclusion criteria: * inflammatory cause of esrd * liver disease, cancer, aids * any infectious disease 2 months before the study * failed kidney graft * hypersensitivity to angiotensin converting enzyme inhibitors or angiotensin receptor blockers * arterial hypotension * pregnancy * treatment with antibiotics, non-steroidal anti-inflammatory drugs, steroids, immunosuppressives, statins, ace inhibitors or arb 3 months previous to the study

Keywords: inflammation telmisartan captopril hemodialysis
urological management of complications of penile constriction devices:

Conditions: Sexual Dysfunction

Summary: wearing a penile ring is justified by international societies of urology (afu, eau, aua) only for the treatment of erectile dysfunction with vacuum. in this case, it is a constriction rubber band that can only be worn for 30 minutes. nowadays, wearing a cockring device for recreational purposes can lead to complications secondary to ischemia caused by strangulation of the penis and/or scrotum. the variety of devices and materials used (metallic and/or alloys in particular) sometimes makes it difficult to remove them, requiring expensive surgery and dedicated equipment. there is no official recommendation for the management of these complications.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * peyronie's disease stable for more than 3 months after 12 to 18 months of evolution * any patient care for this pathology in public or private healthcare hospitals in france exclusion criteria: - refusal to participate

Keywords: penile constriction device cockering emergency care penile strangulation urinary dysfunction
body composition, fitness, and thermoregulation in young boys with type i diabetes vs. healthy soccer players

Conditions: Diabetes

Summary: the study aims to assess differences in body composition, exercise capacity, and thermoregulation between young soccer players with type 1 diabetes and their healthy peers. real-time glycemic monitoring during exercise will provide insights for developing effective diabetes management strategies, enhancing athletes' health and performance.

the aim of the study is to assess differences in body composition, exercise capacity, and exercise-induced thermoregulation between young athletes (soccer players) with type 1 diabetes and their healthy peers (also soccer players). specifically, the study seeks to understand how type 1 diabetes, periodic glycemic fluctuations, and the body's metabolic balance status impact these parameters. by monitoring glycemic levels in real-time during exercise, the research will provide valuable insights into the necessity and frequency of glycemic control for individuals engaging in physical activity of varying intensities. the data obtained from this study may be crucial for developing effective strategies for managing type 1 diabetes in athletes, ultimately contributing to the improvement of their overall health and physical performance. additionally, these findings could inform guidelines and recommendations for safe and effective exercise practices for diabetic athletes.

Eligibility criteria:
inclusion criteria: * active soccer training for at least 5 years exclusion criteria: * comorbidities significantly affecting metabolism and thermoregulation

Keywords: diabetes football exercise thermography